Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1875 1
1895 1
1920 1
1924 1
1925 1
1946 5
1947 7
1948 3
1949 2
1950 3
1951 4
1953 4
1954 3
1955 1
1956 3
1957 2
1958 9
1959 6
1960 10
1961 5
1962 6
1963 12
1964 9
1965 3
1966 14
1967 14
1968 17
1969 20
1970 8
1971 11
1972 9
1973 10
1974 15
1975 10
1976 16
1977 10
1978 18
1979 14
1980 14
1981 6
1982 14
1983 22
1984 15
1985 17
1986 17
1987 19
1988 15
1989 14
1990 18
1991 12
1992 17
1993 27
1994 16
1995 15
1996 23
1997 16
1998 22
1999 22
2000 12
2001 24
2002 33
2003 21
2004 25
2005 24
2006 15
2007 23
2008 27
2009 23
2010 23
2011 29
2012 22
2013 24
2014 26
2015 20
2016 26
2017 25
2018 33
2019 21
2020 31
2021 28
2022 36
2023 35
2024 25
2025 24

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,224 results

Results by year

Filters applied: . Clear all
Page 1
Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study.
Kelly WK, Danila DC, Lin CC, Lee JL, Matsubara N, Ward PJ, Armstrong AJ, Pook D, Kim M, Dorff TB, Fischer S, Lin YC, Horvath LG, Sumey C, Yang Z, Jurida G, Smith KM, Connarn JN, Penny HL, Stieglmaier J, Appleman LJ. Kelly WK, et al. Cancer Discov. 2024 Jan 12;14(1):76-89. doi: 10.1158/2159-8290.CD-23-0964. Cancer Discov. 2024. PMID: 37861461 Free PMC article.
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.
Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, Hussain M, Kelly WK, Liu G, Logothetis C, Nanus D, Stein MN, Rathkopf DE, Slovin SF, Ryan CJ, Sartor O, Small EJ, Smith MR, Sternberg CN, Taplin ME, Wilding G, Nelson PS, Schwartz LH, Halabi S, Kantoff PW, Armstrong AJ; Prostate Cancer Clinical Trials Working Group 3. Scher HI, et al. Among authors: kelly wk. J Clin Oncol. 2016 Apr 20;34(12):1402-18. doi: 10.1200/JCO.2015.64.2702. Epub 2016 Feb 22. J Clin Oncol. 2016. PMID: 26903579 Free PMC article.
Human Kallikrein 2: A Novel Lineage-Specific Surface Target in Prostate Cancer.
Shen F, Smith R, McDevitt T, Menard K, Tian S, Chu G, Chaudhary R, McCann J, Oyer H, Wang SC, Max S, Francis P, Kelly WK, Drake CG. Shen F, et al. Among authors: kelly wk. Clin Cancer Res. 2025 Nov 3;31(21):4543-4556. doi: 10.1158/1078-0432.CCR-25-0950. Clin Cancer Res. 2025. PMID: 40627156 Free PMC article.
CHEST Challenge Turns Twenty.
Danckers M, Miles MC, Chandra S, Kelly WF. Danckers M, et al. Among authors: kelly wf. Chest. 2022 Mar;161(3):860-862. doi: 10.1016/j.chest.2021.11.003. Chest. 2022. PMID: 35256084 No abstract available.
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M; Prostate Cancer Clinical Trials Working Group. Scher HI, et al. Among authors: kelly wk. J Clin Oncol. 2008 Mar 1;26(7):1148-59. doi: 10.1200/JCO.2007.12.4487. J Clin Oncol. 2008. PMID: 18309951 Free PMC article.
Sacituzumab Govitecan in patients with breast cancer brain metastases and recurrent glioblastoma: a phase 0 window-of-opportunity trial.
Balinda HU, Kelly WJ, Kaklamani VG, Lathrop KI, Canola MM, Ghamasaee P, Sareddy GR, Michalek J, Gilbert AR, Surapaneni P, Tiziani S, Pandey R, Chiou J, Lodi A, Floyd JR 2nd, Brenner AJ. Balinda HU, et al. Among authors: kelly wj. Nat Commun. 2024 Aug 7;15(1):6707. doi: 10.1038/s41467-024-50558-9. Nat Commun. 2024. PMID: 39112464 Free PMC article. Clinical Trial.
Germline chromatin.
Schaner CE, Kelly WG. Schaner CE, et al. Among authors: kelly wg. WormBook. 2006 Jan 24:1-14. doi: 10.1895/wormbook.1.73.1. WormBook. 2006. PMID: 18050477 Free PMC article. Review.
Master Transcription Factor Reprogramming Unleashes Selective Translation Promoting Castration Resistance and Immune Evasion in Lethal Prostate Cancer.
Santasusagna S, Zhu S, Jawalagatti V, Carceles-Cordon M, Ertel A, Garcia-Longarte S, Song WM, Fujiwara N, Li P, Mendizabal I, Petrylak DP, Kelly WK, Reddy EP, Wang L, Schiewer MJ, Lujambio A, Karnes J, Knudsen KE, Cordon-Cardo C, Dong H, Huang H, Carracedo A, Hoshida Y, Rodriguez-Bravo V, Domingo-Domenech J. Santasusagna S, et al. Among authors: kelly wk. Cancer Discov. 2023 Dec 12;13(12):2584-2609. doi: 10.1158/2159-8290.CD-23-0306. Cancer Discov. 2023. PMID: 37676710 Free PMC article.
Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import.
Rodriguez-Bravo V, Pippa R, Song WM, Carceles-Cordon M, Dominguez-Andres A, Fujiwara N, Woo J, Koh AP, Ertel A, Lokareddy RK, Cuesta-Dominguez A, Kim RS, Rodriguez-Fernandez I, Li P, Gordon R, Hirschfield H, Prats JM, Reddy EP, Fatatis A, Petrylak DP, Gomella L, Kelly WK, Lowe SW, Knudsen KE, Galsky MD, Cingolani G, Lujambio A, Hoshida Y, Domingo-Domenech J. Rodriguez-Bravo V, et al. Among authors: kelly wk. Cell. 2018 Aug 23;174(5):1200-1215.e20. doi: 10.1016/j.cell.2018.07.015. Epub 2018 Aug 9. Cell. 2018. PMID: 30100187 Free PMC article.
1,224 results